Kinins in humans

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 278, Issue 4 47-4, 2000, Pages

  Duncan, Ann Maree ^a   Kladis, Athena ^a   Jennings, Garry L ^b   Dart, Anthony M ^b   Esler, Murray ^b   Campbell, Duncan J ^a  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Angiotensin converting enzyme inhibition; Bradykinin; Cardiac failure; Kallidin; Reactive hyperemia

Indexed keywords

BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; KININ;

ADULT; ARTICLE; BLOOD LEVEL; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPEREMIA; MALE; MEDIATOR RELEASE; NORMAL HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; URINE LEVEL;

EID: 0033996729     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.2000.278.4.r897     Document Type: Article

References (37)

1. Bhoola KD, Figueroa CD, and Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44:1-80, 1992.
2. Bonner G, Iwersen D, and Shimamoto K. The analytical value for kinin concentration in blood depends on the antiserum used in the bradykinin radioimmunoassay. J Clin Chem Clin Biochem 25: 39-43, 1987.
3. Campbell DJ, Duncan A-M, and Kladis A. Angiotensin converting enzyme inhibition modifies angiotensin, but not kinin peptide levels in atrial tissue. Hypertension 34: 171-175, 1999.
4. Campbell DJ and Kladis A. Simultaneous radioimmunoassay of six angiotensin peptides in arterial and venous plasma of man. J Hypertens 8: 165-172, 1990.
5. Campbell DJ, Kladis A, and Duncan A-M. Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension 21: 155-165, 1993.
6. Campbell DJ, Kladis A, and Duncan A-M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 23: 439-449, 1994.
7. Campbell DJ, Lawrence AC, Kladis A, and Duncan A-M. Strategies for measurement of angiotensin and bradykinin peptides and their metabolites in central nervous system and other tissues. In: Methods in Neurosciences: Peptidases and Neuropeptide Processing, edited by Smith AI. Orlando, FL: Academic, 1995, vol. 23, p. 328-343.
8. Carretero OA and Scicli AG. Local hormonal factors (intracrine, autocrine, and paracrine) in hypertension. Hypertension 18, Suppl I: I-58-I-69, 1991.
9. Cherry PD, Furchgott RF, Zawadzki JV, and Jothianandan D. Role of endothelial cells in relaxation of isolated arteries by bradykinin. Proc Natl Acad Sci USA 79: 2106-2110, 1982.
10. 2 kinin receptors during metabolic anoxia in the rat isolated atria. Can J Physiol Pharmacol 75: 639-645, 1997.
11. Gainer JV, Morrow JD, Lovelend A, King DJ, and Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 339: 1285-1292, 1998.
12. Gardes J, Baussant T, Corvol P, Ménard J, and Alhenc-Gelas F. Effect of bradykinin and kininogens in isolated rat kidney vasoconstricted by angiotensin II. Am J Physiol Renal Fluid Electrolyte Physiol 258: F1273-F1281, 1990.
13. Groves P, Kurz S, Just H, and Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation 92: 3424-3430, 1995.
14. Hilgenfeldt U, Linke R, Riester U, König W, and Breipohl G. Strategy of measuring bradykinin and kallidin and their concentration in plasma and urine. Anal Biochem 228: 35-41, 1995.
15. Hunter WM and Greenwood FC. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 194: 495-496, 1962.
16. Kato H and Enjyoji K. Hydroxylated kininogens and kinins. In: Recent Progress on Kinins Biochemistry and Molecular Biology of the Kallikrein-Kinin System, edited by Fritz H,. Müller-Esterl W, Jochum M, Roscher A, and Luppertz K. Basel: Birkhèuser Verlag, 1992, p. 217-224.
17. Kato H, Matsumura Y, and Maeda H. Isolation and identification of hydroxyproline analogues of bradykinin in human urine. FEBS Lett 232: 252-254, 1988.
18. 22Na in the rat nephron M. J Pharmacol Exp Ther 214: 119-123, 1980.
19. Kokkonen JO, Kuoppala A, Saarinen J, Lindstedt KA, and Kovanen PT. Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase. Circulation 99: 1984-1990, 1999.
20. Kozik A, Moore RB, Potempa J, Imamura T, Rapala-Kozik M, and Travis J. A novel mechanism for bradykinin production at inflammatory sites. Diverse effects of a mixture of neutrophil elastase and mast cell tryptase versus tissue and plasma kallikreins on native and oxidized kininogens. J Biol Chem 273: 33224-33229, 1998.
21. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, and Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure - role of kinins and angiotensin II type 2 receptors. J Clin Invest 99: 1926-1935, 1997.
22. McGiff JC, Carroll MA, and Escalante B. Arachidonate metabolites and kinins in blood pressure regulation. Hypertension 18, Suppl III: III-150-III-157, 1991.
23. Nasjletti A, Colina-Chourio J, and McGiff JC. Disappearance of bradykinin in the renal circulation of dogs. Effects of kininase inhibition. Circ Res 37: 59-65, 1975.
24. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, and Agostoni A. Plasma bradykinin in angio-oedema. Lancet 351:1693-1697, 1998.
25. Pellacani A, Brunner HR, and Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci 87: 567-574, 1994.
26. Piedimonte G, Nadel JA, Long CS, and Hoffman JIE. Neutral endopeptidase in the heart: neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation. Circ Res 75: 770-779, 1994.
27. Regoli D, Rhaleb N-E, Drapeau G, Dion S, Tousignant C, D'Orléans-Juste P, and Devillier P. Basic pharmacology of kinins: pharmacologic receptors and other mechanisms. Adu Exp. Med. Biol. 247A: 399-407, 1989.
28. Rosamilia A, Clements JA, Dwyer PL, Kende M, and Campbell DJ. Activation of the kallikrein kinin system in interstitial cystitis. J Urol 162: 129-134, 1999.
29. Schremmer-Danninger E, Öffner A, Siebeck M, and Roscher AA. B1 bradykinin receptors and carboxypeptidase M are both upregulated in the aorta of pigs after LPS infusion. Biochem Biophys Res Commun 243: 246-252, 1998.
30. Scicli AG, Mindroiu T, Scicli G, and Carretero OA. Blood kinins, their concentration in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen. J Lab Clin Med 100: 81-93, 1982.
31. Shi S-J, Rakugi H, Higashimori K, Higaki J, Mikami H, and Ogihara T. Augmentation of angiotensin II release from isolated mesenteric arteries of Wistar-Kyoto and spontaneously hypertensive rats following nephrectomy. Clin Exp Pharmacol Physiol 21: 767-773, 1994.
32. Shimamoto K, Nakagawa M, and Iimura O. In vivo concentrations of kinins and angiotensins. Horm Metab Res 22, Suppl: 75-79, 1990.
33. Vaz M, Jennings G, Turner A, Cox H, Lambert G, and Esler M. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 96: 3423-3429, 1997.
34. Wiemer G, Schölkens BA, Becker RHA, and Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 18: 558-563, 1991.
35. Wilkinson DJ, Thompson JM, Lambert GW, Jennings GL, Schwarz RG, Jefferys D, Turner AG, and Esler MD. Sympathetic activity in patients with panic disorder at rest, under laboratory mental stress, and during panic attacks. Arch Gen Psych 55: 511-520, 1998.
36. Willis LR, Ludens JH, Hook JB, and Williamson HE. Mechanism of natriuretic action of bradykinin. Am J Physiol 217: 1-5, 1969.
37. Yang XP, Liu YH, Peterson E, and Carretero OA. Effect of neutral endopeptidase 24.11 inhibition on myocardial ischemia/reperfusion injury: The role of kinins. J Cardiovasc Pharmacol 29: 250-256, 1997.